Clinical Trials Logo

Filter by:
  • Available  
  • Page [1]
NCT ID: NCT05462639 Available - Multiple Myeloma Clinical Trials

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

MAGNETISMM17
Start date: n/a
Phase:
Study type: Expanded Access

Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity. This expanded access protocol will provide access to elranatamab until it becomes commercially accessible to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.

NCT ID: NCT04564755 Available - Atopic Dermatitis Clinical Trials

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

Start date: n/a
Phase:
Study type: Expanded Access

This is a multi-center, expanded access protocol to provide access to the investigational product, abrocitinib, to adolescent and adult patients with moderate to severe atopic dermatitis who have inadequate treatment options with available and approved medicated topical and systemic therapies and who are otherwise ineligible for participation in clinical studies with abrocitinib.

NCT ID: NCT03994627 Available - Soft Tissue Sarcoma Clinical Trials

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).

NCT ID: NCT03863119 Available - Clinical trials for Duchenne Muscular Dystrophy

Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy

Start date: n/a
Phase:
Study type: Expanded Access

The intent of this protocol is to provide continued access to vamorolone for subjects in the United States who Have Completed the VBP15-LTE, VBP15- 004, or VBP15-006 protocols (and are thereby ineligible to enroll in another trial of vamorolone therapy), during the time a new drug application for vamorolone is under preparation and review.

NCT ID: NCT03763604 Available - Clinical trials for Metastatic Breast Cancer

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

NCT ID: NCT03601442 Available - Clinical trials for Acute Lymphoblastic Leukemia (ALL)

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Start date: n/a
Phase:
Study type: Expanded Access

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.